Safety and Efficacy of Drug Combinations Against Triple Infections
Not Applicable
Completed
- Conditions
- Parasitic Diseases
- Interventions
- Registration Number
- NCT01050517
- Lead Sponsor
- DBL -Institute for Health Research and Development
- Brief Summary
This randomised, controlled, double blinded clinical study investigates the safety and efficacy of the combination of albendazole, ivermectin and praziquantel in the treatment of children aged 5-18 years co-infected with lymphatic filariasis, schistosomiasis and soil-transmitted helminthiasis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 250
Inclusion Criteria
- Those who will be in class one to six by the time of study
- Aged 5-18 years and found infected with either SCH, any STH or LF for treatment groups 1,2 or 3 or infected with both SCH and LF for treatment group 4 and infected with all the three for treatment group 5
- Who are willing and consent and whose parents will consent, will be included in the study.
Exclusion Criteria
- Those with acute and chronic diseases other than the targeted infections and those with a history of any serious adverse drug reactions will not be included in the study.
- Children with total bilirubin > 50µmol/L and ALAT (Alanine transferase) > 70IU/L will not qualify for recruitment.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 albendazole + ivermectin + praziquantel albendazole + ivermectin + praziquantel 2 albendazole + ivermectin + (1 week later) praziquantel albendazole + ivermectin + (1 week later) praziquantel
- Primary Outcome Measures
Name Time Method adverse reactions 6 weeks
- Secondary Outcome Measures
Name Time Method Efficacy of treatment 6 weeks
Trial Locations
- Locations (1)
Vector Control Division
🇺🇬Kampala, Uganda